Nanostructured Lipid Carriers: A potential drug carrier for cancer chemotherapy

Abstract

Nanotechnology having developed exponentially, the aim has been on therapeutic undertaking, particularly for cancerous disease chemotherapy. Nanostructured lipid carriers have attracted expanding scientific and commercial vigilance in the last couple of years as alternate carriers for the pharmaceutical consignment, particularly anticancer pharmaceuticals. Shortcomings often came across with anticancer mixtures, such as poor solubility, normal tissue toxicity, poor specificity and steadiness, as well as the high incidence rate of pharmaceutical resistance and the rapid degradation, need of large-scale output procedures, a fast release of the pharmaceutical from its carrier scheme, steadiness troubles, the residues of the organic solvents utilized in the output method and the toxicity from the polymer with esteem to the carrier scheme are anticipated to be overcome through use of the Nanostructured Lipid Carrier. In this review the benefits, types, drug release modulations, steadiness and output techniques of NLCs are discussed. In supplement, the function of NLC in cancer chemotherapy is presented and hotspots in research are emphasized. It is foreseen that, in the beside future, nanostructured lipid carriers will be further advanced to consign cytotoxic anticancer compounds in a more efficient, exact and protected manner.

The Impact of Variables on Particle Size of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers; A Comparative Literature Review

“…2 However, these investigated delivery systems show their own drawbacks. Frequently reported disadvantages of colloidal carriers such as liposomes, micro and nanoemulsions, nanocapsules, nanosponges, and polymeric nanoparticles include burst drug release in orallyadministered drugs due to its rapid degradation by the pH of the stomach or by intestinal enzymes and bile salts, limited physical and chemical stability during storage, [3][4][5][6][7][8] difficulty in large-scale production, residues from organic solvents used in preparation of the carriers, some susceptibilities in polymer toxicity, [8][9][10] and too many more to mention. All of these drawbacks suggest that these colloidal drug delivery systems are not ideal for use as drug carriers.…”

“…All of these drawbacks suggest that these colloidal drug delivery systems are not ideal for use as drug carriers. 8 Nanolipid carriers have gained much interest in pharmaceutical sciences for several delivery routes, e.g., dermal, 11,12 oral, 13 parenteral, 14 pulmonary, [15][16][17][18] and ocular. 19,20 Solid lipid nanoparticles (SLNs) were introduced in the early 1990s as drug carriers.…”

Development and optimization of ifosfamide nanostructured lipid carriers for oral delivery using response surface methodology

“…But, the common disadvantages experienced with solid lipid nanoparticles are particles growing, unpredictable gelation tendency, unexpected dynamics of polymorphic transitions and inherent low incorporation rate due to the crystalline structure of the solid lipid (Das and Chaudhury 2011;Muller et al 2002a, b;Selvamuthukumar and Velmurugan 2012). In general, drug molecules stay in between the fatty acid chains or as amorphous clusters in crystal imperfections within SLN matrix.…”

Enhanced in Vitro Anti-Tumor Activity of 5-Azacytidine by Entrapment into Solid Lipid Nanoparticles

“…However, these explored nanoparticulate delivery systems demonstrate their own disadvantages. Commonly reported drawbacks of colloidal carriers such as liposomes, nanosponges, microemulsions and nanoemulsions, polymeric nanoparticles, and nanocapsules are burst drug release, physical and chemical instability during storage, [20][21][22][23] difficulty in industrial fabrication, the presence of organic solvents applied in the production of these systems, some limitations in polymer toxicity 24,25 and many more too numerous to mention. All of these disadvantages suggest that these colloidal drug delivery systems are not perfect.…”

“…All of these disadvantages suggest that these colloidal drug delivery systems are not perfect. 24 Solid lipid nanoparticles (SLNs) were developed in the beginning of the 1990s as drug carriers 26 proposing the superiorities of emulsions, liposomes, and polymeric nanoparticles. The solid lipid matrix is able to protect encapsulated drugs from chemical instability and offer sustaining drug release patterns compared with nanoemulsions.…”